Setting aside the lack of utility of these documents, which provide virtually incomprehensible explanations for demanding price reductions, the information they contain belongs to the sponsor companies, who have every right to delay or prevent their publication.
More companies are exercising their rights, and they are perfectly entitled
July 7, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Clarity successfully completes $203 million institutional placement
July 28, 2025 - - Australian Biotech -
US and EU secure new trade agreement, but 'more to come' on pharmaceuticals
July 28, 2025 - - Latest News -
Hepatitis Australia wants action as new analysis reveals many still missing cures
July 28, 2025 - - Latest News -
Ok for North Korea to have a say on our health responses, but not the US
July 28, 2025 - - Latest News -
Leading stakeholders call for urgency on national genomics framework
July 28, 2025 - - Latest News -
The Dispatched 'Week in Review' Podcast - 27 July
July 27, 2025 - - Podcast -
FDA invites submissions to new rapid review priority program
July 25, 2025 - - Latest News